Updated:
BioMarin Pharmaceutical
BioMarin develops and commercializes medicines for rare and genetically defined diseases, completing its Amicus acquisition in April 2026.
Overview
BioMarin Pharmaceutical is a biotechnology company that develops and commercializes medicines for serious and rare diseases, with a focus on genetically defined conditions. Its business combines commercial therapies with a pipeline of clinical and preclinical development programs. BioMarin completed its acquisition of Amicus Therapeutics on April 27, 2026, when Amicus became a wholly owned subsidiary. The company also uses licensing arrangements alongside its own product development activities. For fiscal 2025, ended December 31, 2025, it reported revenue of approximately $3.221 billion and total assets of approximately $7.594 billion at year-end.
Company overview
- Legal name
- BioMarin Pharmaceutical Inc
- Classification
- Public company
- Incorporated in
- Delaware
- SEC CIK
- 0001048477
- LEI
- NSLL8ITTRR0J5HEMR848
Financials
Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.
| Fiscal year | Period end | Revenue | Total assets | Cash and equivalents | Operating cash flow |
|---|---|---|---|---|---|
| FY2025USD | $3.2B | $7.6B | $1.3B | $828.0M | |
| FY2024USD | $2.9B | $7.0B | $942.8M | $572.8M | |
| FY2023USD | $2.4B | $6.8B | $755.1M | $159.3M | |
| FY2022USD | $2.1B | $6.4B | $724.5M | $175.9M |
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Research BioMarin Pharmaceutical in Altss
Track this company’s investors, transactions and relationships in Altss.